Anti-proliferative effect of Klimaktoplan® on human breast cancer cells

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: With the health concerns of menopausal hormone replacement therapy, alternatives have been sought. Klimaktoplan® is a homeopathic formulation consisting of four main components and has been used for relief of menopausal symptoms for a long time. The study investigated the safety of Klimaktoplan® through its effect on the proliferation of breast cancer (MCF-7) and non-malignant mammary epithelial cells (MCF-10A). Methods: MCF-7 and MCF-10A cells were cultured in 312.5, 625, and 1,250 μg/ml Klimaktoplan®. 17-Beta estradiol (E2) and medroxyprogesterone 17-acetate (MPA) were used for comparison with Klimaktoplan®. E2 only (0.001, 0.01, and 0.1 μM), and the combination of E2 (0.001, 0.01, and 0.1 μM) and MPA (0.01, 0.1, and 1 μM) were tested. Control cells for Klimaktoplan® and E2 groups were treated with dimethylsulfoxide (DMSO), and DMSO + ethanol was used for the combination group. Cellular proliferation was evaluated by the formation of insoluble formazan after incubation of 4 days. Results: Klimaktoplan® had a concentration-dependent anti-proliferative effect on breast cancer cells at 625 and 1,250 μg/ml, while not affecting proliferation of non-malignant mammary cells at any tested concentration. The effect of lactose was evaluated as lactose (the adjuvant of Klimaktoplan®) affect cell growth. E2 and lactose increased the proliferation of both malignant and non-malignant cells. The effect of E2 + MPA on the proliferation of malignant and non-malignant mammary cells was lower than estradiol only, but was higher than control. Conclusions: Klimaktoplan® has an anti-proliferative effect on breast cancer cells, but not for non-malignant mammary epithelial cells, unlike E2 and E2 + P. With further research, KP would be a good alternative or additive in women with menopausal symptoms who wish to avoid conventional E or E + P hormone therapy.

Original languageEnglish
Pages (from-to)833-838
Number of pages6
JournalArchives of Gynecology and Obstetrics
Volume288
Issue number4
DOIs
Publication statusPublished - 2013 Oct 1

Fingerprint

Breast Neoplasms
Medroxyprogesterone Acetate
Breast
Lactose
Dimethyl Sulfoxide
Estradiol
Epithelial Cells
Formazans
Hormone Replacement Therapy
MCF-7 Cells
Ethanol
Cell Proliferation
Hormones
Safety
Health
Growth
Research
Therapeutics

Keywords

  • Klimaktoplan®
  • MCF-10A
  • MCF-7
  • Proliferation

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Anti-proliferative effect of Klimaktoplan® on human breast cancer cells. / Ahn, Ki Hoon; Yi, Kyong Wook; Park, Hyun-Tae; Shin, Jung-Ho; Hur, Jun Young; Kim, Sun Haeng; Kim, Tak.

In: Archives of Gynecology and Obstetrics, Vol. 288, No. 4, 01.10.2013, p. 833-838.

Research output: Contribution to journalArticle

@article{810aada1de4649c28b3695aac5838917,
title = "Anti-proliferative effect of Klimaktoplan{\circledR} on human breast cancer cells",
abstract = "Objective: With the health concerns of menopausal hormone replacement therapy, alternatives have been sought. Klimaktoplan{\circledR} is a homeopathic formulation consisting of four main components and has been used for relief of menopausal symptoms for a long time. The study investigated the safety of Klimaktoplan{\circledR} through its effect on the proliferation of breast cancer (MCF-7) and non-malignant mammary epithelial cells (MCF-10A). Methods: MCF-7 and MCF-10A cells were cultured in 312.5, 625, and 1,250 μg/ml Klimaktoplan{\circledR}. 17-Beta estradiol (E2) and medroxyprogesterone 17-acetate (MPA) were used for comparison with Klimaktoplan{\circledR}. E2 only (0.001, 0.01, and 0.1 μM), and the combination of E2 (0.001, 0.01, and 0.1 μM) and MPA (0.01, 0.1, and 1 μM) were tested. Control cells for Klimaktoplan{\circledR} and E2 groups were treated with dimethylsulfoxide (DMSO), and DMSO + ethanol was used for the combination group. Cellular proliferation was evaluated by the formation of insoluble formazan after incubation of 4 days. Results: Klimaktoplan{\circledR} had a concentration-dependent anti-proliferative effect on breast cancer cells at 625 and 1,250 μg/ml, while not affecting proliferation of non-malignant mammary cells at any tested concentration. The effect of lactose was evaluated as lactose (the adjuvant of Klimaktoplan{\circledR}) affect cell growth. E2 and lactose increased the proliferation of both malignant and non-malignant cells. The effect of E2 + MPA on the proliferation of malignant and non-malignant mammary cells was lower than estradiol only, but was higher than control. Conclusions: Klimaktoplan{\circledR} has an anti-proliferative effect on breast cancer cells, but not for non-malignant mammary epithelial cells, unlike E2 and E2 + P. With further research, KP would be a good alternative or additive in women with menopausal symptoms who wish to avoid conventional E or E + P hormone therapy.",
keywords = "Klimaktoplan{\circledR}, MCF-10A, MCF-7, Proliferation",
author = "Ahn, {Ki Hoon} and Yi, {Kyong Wook} and Hyun-Tae Park and Jung-Ho Shin and Hur, {Jun Young} and Kim, {Sun Haeng} and Tak Kim",
year = "2013",
month = "10",
day = "1",
doi = "10.1007/s00404-013-2849-1",
language = "English",
volume = "288",
pages = "833--838",
journal = "Archives of Gynecology and Obstetrics",
issn = "0932-0067",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Anti-proliferative effect of Klimaktoplan® on human breast cancer cells

AU - Ahn, Ki Hoon

AU - Yi, Kyong Wook

AU - Park, Hyun-Tae

AU - Shin, Jung-Ho

AU - Hur, Jun Young

AU - Kim, Sun Haeng

AU - Kim, Tak

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Objective: With the health concerns of menopausal hormone replacement therapy, alternatives have been sought. Klimaktoplan® is a homeopathic formulation consisting of four main components and has been used for relief of menopausal symptoms for a long time. The study investigated the safety of Klimaktoplan® through its effect on the proliferation of breast cancer (MCF-7) and non-malignant mammary epithelial cells (MCF-10A). Methods: MCF-7 and MCF-10A cells were cultured in 312.5, 625, and 1,250 μg/ml Klimaktoplan®. 17-Beta estradiol (E2) and medroxyprogesterone 17-acetate (MPA) were used for comparison with Klimaktoplan®. E2 only (0.001, 0.01, and 0.1 μM), and the combination of E2 (0.001, 0.01, and 0.1 μM) and MPA (0.01, 0.1, and 1 μM) were tested. Control cells for Klimaktoplan® and E2 groups were treated with dimethylsulfoxide (DMSO), and DMSO + ethanol was used for the combination group. Cellular proliferation was evaluated by the formation of insoluble formazan after incubation of 4 days. Results: Klimaktoplan® had a concentration-dependent anti-proliferative effect on breast cancer cells at 625 and 1,250 μg/ml, while not affecting proliferation of non-malignant mammary cells at any tested concentration. The effect of lactose was evaluated as lactose (the adjuvant of Klimaktoplan®) affect cell growth. E2 and lactose increased the proliferation of both malignant and non-malignant cells. The effect of E2 + MPA on the proliferation of malignant and non-malignant mammary cells was lower than estradiol only, but was higher than control. Conclusions: Klimaktoplan® has an anti-proliferative effect on breast cancer cells, but not for non-malignant mammary epithelial cells, unlike E2 and E2 + P. With further research, KP would be a good alternative or additive in women with menopausal symptoms who wish to avoid conventional E or E + P hormone therapy.

AB - Objective: With the health concerns of menopausal hormone replacement therapy, alternatives have been sought. Klimaktoplan® is a homeopathic formulation consisting of four main components and has been used for relief of menopausal symptoms for a long time. The study investigated the safety of Klimaktoplan® through its effect on the proliferation of breast cancer (MCF-7) and non-malignant mammary epithelial cells (MCF-10A). Methods: MCF-7 and MCF-10A cells were cultured in 312.5, 625, and 1,250 μg/ml Klimaktoplan®. 17-Beta estradiol (E2) and medroxyprogesterone 17-acetate (MPA) were used for comparison with Klimaktoplan®. E2 only (0.001, 0.01, and 0.1 μM), and the combination of E2 (0.001, 0.01, and 0.1 μM) and MPA (0.01, 0.1, and 1 μM) were tested. Control cells for Klimaktoplan® and E2 groups were treated with dimethylsulfoxide (DMSO), and DMSO + ethanol was used for the combination group. Cellular proliferation was evaluated by the formation of insoluble formazan after incubation of 4 days. Results: Klimaktoplan® had a concentration-dependent anti-proliferative effect on breast cancer cells at 625 and 1,250 μg/ml, while not affecting proliferation of non-malignant mammary cells at any tested concentration. The effect of lactose was evaluated as lactose (the adjuvant of Klimaktoplan®) affect cell growth. E2 and lactose increased the proliferation of both malignant and non-malignant cells. The effect of E2 + MPA on the proliferation of malignant and non-malignant mammary cells was lower than estradiol only, but was higher than control. Conclusions: Klimaktoplan® has an anti-proliferative effect on breast cancer cells, but not for non-malignant mammary epithelial cells, unlike E2 and E2 + P. With further research, KP would be a good alternative or additive in women with menopausal symptoms who wish to avoid conventional E or E + P hormone therapy.

KW - Klimaktoplan®

KW - MCF-10A

KW - MCF-7

KW - Proliferation

UR - http://www.scopus.com/inward/record.url?scp=84885379086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885379086&partnerID=8YFLogxK

U2 - 10.1007/s00404-013-2849-1

DO - 10.1007/s00404-013-2849-1

M3 - Article

C2 - 23595584

AN - SCOPUS:84885379086

VL - 288

SP - 833

EP - 838

JO - Archives of Gynecology and Obstetrics

JF - Archives of Gynecology and Obstetrics

SN - 0932-0067

IS - 4

ER -